These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16431124)

  • 21. Critical review of the management of early-stage breast cancer in elderly women.
    Passage KJ; McCarthy NJ
    Intern Med J; 2007 Mar; 37(3):181-9. PubMed ID: 17316337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical review of microarray-based prognostic tests and trials in breast cancer.
    Koscielny S
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):47-50. PubMed ID: 18197005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of applied research for prognosis and therapy of breast cancer.
    Barginear MF; Bradley T; Shapira I; Budman DR
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):223-34. PubMed ID: 18243013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet.
    Dolinsky CM; Wei SJ; Hampshire MK; Metz JM
    Breast J; 2006; 12(4):324-30. PubMed ID: 16848841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating surgery into treatment paradigms for organ preservation: tailoring treatment to biology improves outcomes.
    Wolf GT
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S4-7. PubMed ID: 17848290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor cells in breast cancer.
    Ignatiadis M; Georgoulias V; Mavroudis D
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):55-60. PubMed ID: 18197007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecularly targeted therapies for malignant gliomas: advances and challenges.
    Penas-Prado M; Gilbert MR
    Expert Rev Anticancer Ther; 2007 May; 7(5):641-61. PubMed ID: 17492929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TIMP-1 as a tumor marker in breast cancer--an update.
    Würtz SO; Schrohl AS; Mouridsen H; Brünner N
    Acta Oncol; 2008; 47(4):580-90. PubMed ID: 18465326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
    Henry NL; Hayes DF
    Oncologist; 2006 Jun; 11(6):541-52. PubMed ID: 16794234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
    Monnier A
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
    Abu-Khalaf MM; Harris L
    Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
    [No Abstract]   [Full Text] [Related]  

  • 34. Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges.
    van der Vegt B; de Bock GH; Hollema H; Wesseling J
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):1-11. PubMed ID: 18848465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Breast cancer and molecular markers].
    Ishioka C
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1261-8. PubMed ID: 18701834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
    Nagasaki K; Miki Y
    Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient heterogeneity in clinical trials.
    Simon R
    Cancer Treat Rep; 1980; 64(2-3):405-10. PubMed ID: 7407777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Breast cancer: pathology, the cornerstone of therapeutic decision].
    Fiche M; Lehr HA; Perey L; Delaloye JF; Jeanneret-Sozzi W; Bauer J; Zaman K
    Rev Med Suisse; 2007 Jul; 3(119):1737-42. PubMed ID: 17727094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
    Cooper R; Kaanders JH
    Eur J Cancer; 2005 Jun; 41(9):1261-6. PubMed ID: 15939261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy for locally advanced breast cancer.
    Specht J; Gralow JR
    Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.